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Abstract
BACKGROUND
Obesity is a major health problem due to its high prevalence. The relationship
between obesity and cardiovascular disease is unclear. Some studies agree that
certain conditions associated with obesity, such as physical inactivity or
cardiovascular risk factors, are responsible for cardiovascular risk excess among
obese people. Carotid intima-media thickness and carotid plaques (CP) have been
associated with cardiovascular adverse events in healthy populations, and recent
data suggest a higher prevalence of subclinical carotid atherosclerosis in obese
and metabolically unhealthy patients. However, there are no studies correlating
subclinical atherosclerosis and adverse events (AE) in obese subjects.
AIM
To determine the association between carotid disease and AE in obese patients
with negative exercise echocardiography (EE).
METHODS
From January 1, 2006 to December 31, 2010, 2000 consecutive patients with a
suspicion of coronary artery disease were submitted for EE and carotid
ultrasonography. Exclusion criteria included previous vascular disease, left
ventricular ejection fraction < 50%, positive EE, significant valvular heart disease
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and inferior to submaximal EE. An AE was defined as all-cause mortality,
myocardial infarction and cerebrovascular accident. Subclinical atherosclerosis
was defined as CP presence according to Manheim and the American Society of
Echocardiography Consensus.
RESULTS
Of the 652 patients who fulfilled the inclusion criteria, 226 (34.7%) had body mass
indexes ≥ 30 kg/m2, and 76 of them (33.6%) had CP. During a mean follow-up
time of 8.2 (2.1) years, 27 AE were found (11.9%). Mean event-free survival at 1, 5
and 10 years was 99.1% (0.6), 95.1% (1.4) and 86.5% (2.7), respectively. In
univariate analysis, CP predicted AE [hazard ratio (HR) 2.52, 95% confidence
interval (CI) 1.17-5.46; P = 0.019]. In multivariable analysis, the presence of CP
remained a predictor of AE (HR 2.26, 95%CI 1.04-4.95, P = 0.041). Other
predictors identified were glomerular filtration rate (HR 0.98, 95%CI 0.96-0.99; P
= 0.023), peak metabolic equivalents (HR 0.83, 95%CI 0.70–0.99, P = 0.034) and
moderate mitral regurgitation (HR 5.02, 95%CI 1.42–17.75, P = 0.012).
CONCLUSION
Subclinical atherosclerosis defined by CP predicts AE in obese patients with
negative EE. These patients could benefit from aggressive prevention measures.
Key words: Carotid intima media thickness; Carotid plaque; Carotid disease; Myocardial
infarction; Mortality; Stroke; Exercise stress echocardiography
©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
Core tip: There is a controversy about obesity and coronary artery disease prognosis.
Several studies suggest a greater influence of physical inactivity than that of body mass
index on mortality, but there are no data addressing the influence of subclinical
atherosclerosis in patients with suspected coronary artery disease submitted to a non-
invasive treadmill test. Our study shows that clinical atherosclerosis in other vascular
beds, such as carotid plaque presence, is a greater predictor than functional capacity.
These patients could benefit from aggressive prevention measures.
Citation: Vidal-Perez R, Franco-Gutiérrez R, Pérez-Pérez AJ, Franco-Gutiérrez V, Gascón-
Vázquez A, López-López A, Testa-Fernández AM, González-Juanatey C. Subclinical carotid
atherosclerosis predicts all-cause mortality and cardiovascular events in obese patients with
negative exercise echocardiography. World J Cardiol 2019; 11(1): 24-37
URL: https://www.wjgnet.com/1949-8462/full/v11/i1/24.htm
DOI: https://dx.doi.org/10.4330/wjc.v11.i1.24
INTRODUCTION
Obesity and body mass index (BMI) have increased in every nation in the last years,
associating  with  a  concomitant  augmentation  in  the  prevalence  of  traditional
cardiovascular risk factors[1]. Obesity is independently associated with mortality and
cardiovascular disease[2,3], likely through adverse remodelling of the arteries and a
higher prevalence of subclinical vascular disease[4,5]. However, once cardiovascular
disease (CVD) is established, the studies published so far show contradictory results.
Some investigations suggest a protective effect of obesity[6,7]. Other researchers suggest
that it is not the obesity itself, but certain associated characteristics, such as physical
inactivity or metabolic risk factors, that explain the increased risk attributed to obese
people. This suggestion gives rise to concepts such as metabolically healthy obesity[8,9]
or fit obese patients[10,11].
Several epidemiological studies have demonstrated an independent association of
carotid disease, defined as carotid plaques (CP) or carotid intima media thickness
(CIMT), with overall mortality and cardiovascular events[12-16]. Although a negative
treadmill  exercise  stress  echocardiography  is  associated  with  good  prognosis,
according to European guidelines on stable coronary artery disease (CAD)[17],  the
annualized event rates defined as overall mortality and adverse cardiac events are
nearly 1% in contemporary series[18]. It therefore seems necessary to define other tools
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to decrease adverse events (AE) in these patients. As we previously described, carotid
disease  has  been  associated  with  adverse  cardiovascular  events[12-15],  and  one
advantage of carotid ultrasonography is that it is not invasive and can be performed
immediately after the exercise echocardiography (EE) using the same equipment.
Moreover, ultrasound assessment of carotid arteries in patients with suspected CAD
without  known  atherosclerotic  disease  is  a  class  IIa  C  recommendation  in  the
aforementioned European guidelines[17].
There are no studies addressing the value of subclinical atherosclerosis, defined as
carotid disease, and AE in obese patients with or without CVD. The Multi-Ethnic
Study of Atherosclerosis found significantly higher CIMT values in obese patients
after  adjustment  for  traditional  CVD risk factors[4]  or  high-sensitivity  C-reactive
protein values[5]. Recent publications have found a higher percentage of subclinical
carotid disease among metabolically unhealthy subjects  compared to those with
metabolic disease absence in obese people either with[19] or without CAD[20]. These
studies emphasize the concept of obesity and associated phenotypes as predictors of
AE. The aim of the current study is to determine if carotid disease is a predictor of AE
in obese patients with CAD suspicion and negative treadmill stress echocardiography.
MATERIALS AND METHODS
We performed a retrospective cohort study of patients without significant heart or
vascular disease, with a BMI ≥ 30 kg/m2 and coronary artery disease suspicion with
negative EE who were submitted for carotid ultrasonography.
Study population
Between January 2006 and December 2010, 2000 patients were submitted for stress
echocardiography and carotid ultrasonography in our centre. Of them, 226 (11.3%)
were included. Exclusion criteria included previous CAD [n = 702 (35.1%)], failure to
achieve submaximal predicted heart rate [n = 159 (8.0%)], positive EE [n = 173 (8.7%)],
hereditary cardiac disease (e.g., Brugada syndrome, hypertrophic cardiomyopathy) [n
= 25 (1.3%)], pharmacological stress test [n = 31 (1.6%)], previous stroke or transient
ischaemic attack [n = 52 (2.6%)], peripheral artery disease [n = 31 (1.6%)], valvular
heart disease, defined as aortic stenosis of any aetiology, mitral rheumatic stenosis or
more than moderate valve regurgitation [n = 67 (3.4%)], planned revascularization [n
= 4 (0.2%)], left ventricular ejection fraction less than 50% [n = 9 (0.5%)], loss during
follow-up [n  = 21 (1.1%)], technical problems accessing the stored images [n  = 73
(3.7%)]  and BMI < 30 kg/m2  [n  =  426 (21.3%)].  All  patients  signed the informed
consent before performing the test. The study was approved by the Regional Ethics
Committee. Figure 1 summarizes the selection criteria.
Demographic and clinical characteristics as well as CAD pre-test probabilities (PTP)
were collected from available medical records at the time of the first clinical visit
when EE was requested. Baseline echocardiography, carotid ultrasonography and
stress testing data were collected from digitally stored images and medical records at
the time of EE performance. CAD PTP and Systematic Coronary Risk Evaluation
(SCORE)  were  assessed  according  to  current  European  Society  of  Cardiology
guidelines[1,17]. Treatment data were collected from medical records obtained at the
first visit after EE performance. Of the 226 patients, 172 (76.1%) were evaluated the
same day after EE performance. For the 54 patients that were not evaluated the same
day, the median time between EE and first medical was 13.5 d (interquartile range
47.3).
Exercise stress echocardiography
Physiological parameters such as blood pressure, heart rate, and a 12-lead ECG were
registered at baseline and at each stage of the treadmill stress protocol. The Bruce
treadmill protocol was the preferred method of exercise, but Naughton was employed
in a minority of subjects. A submaximal test was defined as an achievement of 85% of
the  age-predicted  heart  rate.  EE  was  prematurely  stopped  in  case  of  physical
exhaustion, significant arrhythmia, severe hypertension or hypotensive response.
Electrocardiographic changes suggestive of myocardial ischaemia during testing were
defined as a new ST-segment deviation of 1 mm or more, measured at 80 ms after the
J point.
Echocardiographic  views  were  attained  at  rest,  peak  and  immediately  after
exercise,  and digitally stored for later comparisons.  Assessment of  regional  wall
motion was done in a 17-segment model of the left ventricle by using a motility score
that ranged from 1 to 4, depending on its motion. Baseline and exercise wall motion
score index were calculated as average scores of the 17 segments at rest and peak
exercise, respectively. With the exception of isolated hypokinesia of the inferobasal
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Figure 1
Figure 1  Flowchart of the 2000 patients submitted for exercise echocardiography. EE: Exercise echocardiography.
segment  and  worsening  from  akinesia  to  dyskinesia,  exercise-induced
echocardiography  ischaemia  was  defined  as  new  or  worsening  wall  motion
abnormalities developed during the stress test.  When ischaemic changes affected
three or more myocardial segments, the exercise test was considered as extensive
ischemia, while multivessel ischaemia was defined when wall motion abnormalities
were detected in two or more different coronary territories[21].
Carotid ultrasonography
The patients were submitted to carotid ultrasonography immediately after the EE
performance using the same ultrasound equipment (Philips iE33; Philips Medical
Systems, Best, Holland). The ARIC protocol study[12] and expert consensus[22-24] were
followed for the CIMT measurement. CP was defined as focal structures invading 0.5
mm or more into the arterial  lumen, presenting an increase of at  least 50% in its
thickness compared to the neighbouring CIMT value, or a CIMT greater than 1.5 mm
as measured from the intima-lumen limit to the media adventitia limit[22-24].  Semi-
automated edge recognition software was used (QLAB; Philips 110 Medical Systems,
Andover, MA, United States).
Subclinical  atherosclerosis  was  defined  as  a  binary  variable  as  CP
presence/absence.  Both  carotid  ultrasonography  and  EE  stored  images  were
examined by two cardiologists with broad experience in cardiac and carotid imaging
who were blinded to the AE. A third expert reviewed the images in case of any doubt
or disagreement.
End points
Follow-up data were obtained from the hospital database, medical records and death
certificates. In the case of doubt, the Regional Mortality Registry was consulted. AE
was defined as a combined endpoint of all-cause mortality, myocardial infarction and
cerebrovascular accident. Myocardial infarction was defined as specified by the third
universal definition of the myocardial infarction expert consensus document[25]. Stroke
was defined as a loss of neurological function caused by an ischaemic event that
lasted for more than 24 h and left residual signs.
Statistical analysis
No statistical sample-size calculation was done in our study. On the one hand, this
was an innovative unicentric study in terms of using carotid ultrasonography in obese
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patients with an EE with good prognosis. On the other hand, no previously published
studies were found for statistical determination of sample size calculations.
Continuous variables were reported as the mean (standard deviation) or median
(interquartile  range)  depending on Shapiro-Wilk normality test  results,  whereas
categorical variables were reported as percentages. Cumulative death, myocardial
infarction and cerebrovascular accident curves were calculated by the Kaplan-Meier
method and compared using the log rank-test. Cox proportional-hazards regression
was used for both univariate and multivariate analyses. All variables with P values
less or equal to 0.2 were included in the multivariable analysis, and a retention set of
0.1 was applied. A P value of 0.05 or less was considered to be statistically significant.
RESULTS
Of the 226 patients, 76 (33.6%) had subclinical atherosclerosis defined by CP presence.
Patients with CP were older (P < 0.01), with a higher prevalence of hypertension (P =
0.002) and dyslipidaemia (P = 0.027), higher SCORE (P < 0.001), lower glomerular
filtration rate (P < 0.001), lower high-density lipoprotein cholesterol (P = 0.043) and
higher  triglycerides  (P  =  0.011).  This  group also  showed a  higher  percentage of
patients  with  intermediate-to-high  PTP  for  CAD  and  lower  percentage  of
cardiovascular  risk  factor–free  subjects  (P  <  0.001).  Regarding  basal
echocardiography, there were no differences in basal ejection fraction, but CP subjects
had more mitral regurgitation (P = 0.001). Heart rate (P < 0.001), exercise time (P =
0.011) and metabolic equivalents (METs) (P  = 0.015) were lower in the CP group,
whereas mean CIMT (P < 0.001) and CIMT > 0.9 mm (P < 0.001) were higher. Patients
with CP were more frequently on angiotensin II receptor blockers (P = 0.001), calcium
channel  blockers (P  = 0.011),  statins (P  = 0.043)  and oral  antidiabetic  (P  = 0.030)
treatment. The baseline characteristics are summarized in Tables 1 and 2.
Adverse events
During a mean follow-up of 8.0 (2.2) years, six (2.7%) non-ST elevation myocardial
infarctions, two (0.9%) ST elevation myocardial infarctions, nine (4.0%) strokes and 15
(6.6%) deaths were recorded, for a total of 27 (11.9%) AE.
Kaplan–Meier adverse event-free survival at 1, 2, 3, 5 and 10 years was 99.1% (0.6),
98.7% (0.8),  96.9% (1.2),  95.1 (1.4%) and 86.5% (2.7%), respectively. Kaplan-Meier
event-free survival was significantly higher in the non-CP group, with 99.3% (0.7)
event-free survival at 1 and 2 years, 98.7% (0.9) at 2 and 3 years, 97.3% (1.3) at 5 years
and 89.3% (3.5) at 10 years vs 98.7% (1.3) at 1 year, 97.4 (1.8%) at 2 and 3 years, 93.4
(2.8) at 5 years and 80.7% (5.0) at 10 years in the CP group (P = 0.015) ( Figure 2).
Univariate analysis
Age (P < 0.001), glomerular filtration rate (P = 0.002), moderate mitral regurgitation (P
= 0.007), cardiorespiratory fitness expressed in METs (P = 0.001) and CP presence (P =
0.019) were associated in univariate analysis with AE.
Multivariate analysis
Multivariable analysis showed that glomerular filtration rate (P = 0.023), moderate
mitral regurgitation (P = 0.012), peak METs during the EE (P = 0.034) and CP (P =
0.041) were independent predictors of AE. Tables 3 and 4 show the univariate and
multivariate analysis results.
DISCUSSION
To the  best  of  our  knowledge,  this  is  the  first  article  that  correlates  subclinical
atherosclerosis with AE in obese patients,  and specifically in obese patients with
suspicion of ischaemic heart disease and good prognoses from EE.
Recent data from the Clinical Outcomes Utilizing Revascularization and Aggressive
Drug Evaluation show that mortality in stable CAD is not negligible, with nearly 25%
of patients dying during a mean follow-up of 10.5 years[26]. Moreover, the composite
outcome of death, nonfatal myocardial infarction and stroke at a median follow-up
period of 4.6 years has been approximately 20%[27]. For that reason, it is important to
find predictors  of  evolution beyond the  classic  clinical,  echocardiography,  non-
invasive and invasive CAD risk factors[17].
Our study shows that CP increased the probability of an AE in obese patients with
CAD suspicion and negative EE by 2.26.  Similar findings were obtained in other
studies  performed in  ischaemic  patients[28-34].  In  the  Angina  Prognosis  Study  in
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Table 1  Baseline characteristics
n = 226 No plaque, n = 150 Plaque, n = 76 P value
Age 63.2 (11.4) 60.6 (12.1) 68.2 (7.3) < 0.001a
Male sex 106 (46.9%) 64 (42.7%) 42 (55.3%) 0.099
Hypertension 166 (73.5%) 100 (66.7%) 66 (86.8%) 0.002a
Diabetes mellitus 45 (19.9%) 24 (16.0%) 21 (27.6%) 0.058
Dyslipidaemia 124 (54.9%) 74 (49.3%) 50 (65.8%) 0.027a
Current smoker 55 (24.3%) 36 (24.0%) 19 (25.0%) 0.999
Family history of premature CAD 17 (7.5%) 13 (8.7%) 4 (5.3%) 0.516
BMI, kg/m2 33.3 (4.1) 33.2 (4.5) 33.4 (3.0) 0.694
Obesity 0.033a
Grade 1 179 (79.2%) 126 (84.0%) 53 (69.7%)
Grade 2 39 (17.3%) 19 (12.7%) 20 (26.3%)
Grade 3 8 (3.5%) 5 (3.3%) 3 (3.9%)
No cardiovascular risk factors 29 (12.8%) 28 (18.7%) 1 (1.3%) < 0.001a
SCORE < 0.001a
Low-risk, < 1% 29 (12.8%) 28 (18.7%) 1 (1.3%)
Moderate-risk, 1%-5% 113 (50.0%) 78 (52.0%) 35 (46.1%)
High risk, 5%-10% 33 (14.6%) 20 (13.3%) 13 (17.1%)
Very high-risk, ≥ 10% 49 (21.7%) 24 (16.0%) 25 (32.9%)
Not classifiable 2 (0.9%) 0 2 (2.6%)
CAD PTP 0.017a
< 15% 10 (4.4%) 10 (6.7%) 0
15-65% 180 (79.6%) 121 (80.7%) 59 (77.6%)
65-85% 36 (15.9%) 19 (12.7%) 17 (22.4%)
> 85% 0 (0%) 0 (0%) 0 (0%)
Fasting plasma glucose, mg/dL 113.8 (32.2) 112.5 (33.4) 116.6 (29.5) 0.369
Glomerular filtration rate, mL/min/1.73 m2 87.6 (25.4) 91.4 (27.1) 79.7 (20.3) < 0.001a
Total cholesterol, mg/dL 199.6 (40.5) 196.9 (38.5) 205.0 (43.9) 0.159
HDL cholesterol, mg/dL 48.6 (12.3) 49.6 (13.4) 46.5 (9.1) 0.043a
Triglycerides, mg/dL 143.6 (75.9) 133.0 (60.0) 164.8 (97.6) 0.011a
LDL cholesterol, mg/dL 122.1 (34.6) 120.2 (34.1) 125.9 (35.8) 0.257
Atrial fibrillation 26 (11.5%) 14 (9.3%) 12 (15.8%) 0.224
Treatment after EE
Angiotensin-converting enzyme inhibitor 29 (12.8%) 16 (10.7%) 13 (17.1%) 0.247
Angiotensin II receptor blockers 99 (43.8%) 54 (36.0%) 45 (59.2%) 0.001a
Beta-blockers 72 (31.9%) 44 (29.3%) 28 (36.8%) 0.32
Calcium channel blockers 53 (23.5%) 27 (18.0%) 26 (34.2%) 0.011a
Nitrates 21 (9.3%) 13 (8.7%) 8 (10.5%) 0.832
Statins 111 (49.1%) 66 (44.0%) 45 (59.2%) 0.043a
Ezetimibe 6 (2.7%) 3 (2.0%) 3 (3.9%) 0.673
Fibrates 10 (4.4%) 5 (3.3%) 5 (6.6%) 0.476
Omega−3 fatty acids 4 (1.8%) 3 (2.0%) 1 (1.3%) 1
Antiplatelet drugs 109 (48.2%) 67 (44.7%) 42 (55.3%) 0.172
Anticoagulants drugs 17 (7.5%) 8 (5.3%) 9 (11.8%) 0.137
Oral antidiabetic drugs 28 (12.4%) 13 (8.7%) 15 (19.7%) 0.030a
Insulin treatment 5 (2.2%) 2 (1.3%) 3 (3.9%) 0.338
aP < 0.05. BMI: Body mass index; CAD: Coronary artery disease; EE: Exercise echocardiography; HDL cholesterol: High density lipoprotein cholesterol;
LDL cholesterol: Low density lipoprotein cholesterol; PTP: Pre-test probability; SCORE: Systematic COronary Risk Evaluation.
Stockholm[28],  CIMT  could  not  predict  AE  defined  as  cardiovascular  death  or
cardiovascular events, while CP had a tendency (P = 0.056) to predict them in 809
patients younger than 70 years with clinical suspicion of CAD. Compared to our
study, their patients were younger, more frequently male, with a lower percentage of
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Table 2  Baseline echocardiography, treadmill exercise stress echocardiography and carotid ultrasonography characteristics
n = 226 No plaque, n = 150 Plaque, n = 76 P value
Baseline echocardiography
Baseline ejection fraction, % 64.6 (5.2) 64.5 (5.2) 64.7 (5.3) 0.823
Mitral regurgitation 82 (36.3%) 43 (28.7%) 39 (51.3%) 0.001a
Aortic regurgitation 57 (25.2%) 33 (22.0%) 24 (31.6%) 0.16
Tricuspid regurgitation 116 (51.3%) 73 (48.7%) 43 (56.6%) 0.325
Pulmonary regurgitation 3 (1.3%) 3 (2.0%) 0 (0%) 0.553
Pulmonary artery systolic pressure, mmHg 32.6 (7.3) 30.5 (5.8) 35.1 (6.2) 0.013a
Treadmill exercise stress echocardiography
Stress protocol 0.778
Naughton 14 (6.2%) 10 (6.7%) 4 (5.3%)
Bruce 212 (93.8%) 140 (93.3%) 72 (94.7%)
Systolic blood pressure
Baseline 141.8 (18.8) 140.7 (18.7) 143.9 (18.9) 0.222
Peak 197.6 (23.8) 196.6 (23.0) 199.7 (25.4) 0.361
Heart rate
Baseline 73.6 (12.4) 74.0 (11.9) 72.8 (13.5) 0.409
Peak 146.0 (13.1) 148.2 (13.4) 141.7 (11.5) < 0.001a
Percentage 93.1 (5.6) 93.0 (5.5) 93.3 (5.8) 0.718
Maximal stress test 26 (11.5%) 17 (11.3%) 9 (11.8%) 1
Rate-pressure, × 103 mmHg beats/min
Basal 10.5 (2.4) 10.4 (2.3) 10.5 (2.6) 0.831
Peak 28.9 (4.4) 29.1 (4.4) 28.3 (4.3) 0.174
Exercise time, min 8.6 (2.9) 8.1 (2.9) 7.1 (2.4) 0.011a
METs 8.5 (2.9) 8.8 (3.1) 7.9 (2.3) 0.015a
Carotid ultrasonography
CIMT, mm 0.80 (0.20) 0.74 (0.18) 0.91 (0.18) < 0.001a
CIMT > 0.9 mm 62 (27.4%) 27 (18.0%) 35 (46.1%) < 0.001a
aP < 0.05. CIMT: Carotid intima media thickness; METs: Metabolic equivalents.
traditional  cardiovascular  risk  factors.  More  importantly,  14%  of  subjects  had
previous  myocardial  infarction,  BMI  was  not  reported,  there  was  no  prognosis
assessment by non-invasive stress tests, and the CP definition was different from ours.
Petersen  et  al[29]  reported  CP  presence,  especially  heterogeneous  plaques,  as  a
predictor of all-cause deaths in 541 hospitalized cardiological patients, 25% of them
with a BMI > 30 kg/m2, after a median follow-up of 34 mo. Recently, Sirimarco et al[30]
detected  CP  presence  as  a  predictor  of  a  composite  of  first  occurrence  of
cardiovascular death, myocardial infarction, or coronary hospitalization during a
follow-up period of 4 years in 45,227 middle-aged patients (45 years or more). In
addition, CP in this study also predicted three or more cardiovascular risk factors or
established  CAD,  cerebrovascular  disease  or  peripheral  artery  disease  in  these
patients,  28.1% of  whom had BMI ≥  30  kg/m2.  Both  studies  had heterogeneous
populations,  with 64% of patients diagnosed with ischaemic heart  disease in the
Petersen study and 55.6% with CAD (defined as stable angina, prior acute coronary
event,  history  of  percutaneous  coronary  intervention or  coronary  artery  bypass
grafting) in the Reduction of Atherothrombosis for Continued Health Registry. A non-
invasive stress test was not performed in the CAD patients. Like ours, their patients
with  CP were  older  and had a  higher  prevalence  of  cardiovascular  risk  factors.
Studies  involving  patients  with  CAD  assessed  by  angiography  have  also  been
published. Komorovsky et al[31] identified echogenic or calcified CP as a predictor of
cardiac death, non-fatal myocardial infarction, and rehospitalization for unstable
angina  in  337  consecutive  patients  with  acute  coronary  syndrome submitted  to
coronary angiography. Along the same lines, Zielinski et al[32]  found a significant
association between CIMT and death from all causes, stroke, or myocardial infarction
(P = 0.010) in hypertensive patients with CAD, defined as ≥ 50% stenosis by coronary
angiography and a mean BMI of 28.6 (3.8) kg/m2. Park et al[33] found CP as a predictor
of cardiac death and hard major AE (death, stroke or myocardial infarction) in a
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Figure 2
Figure 2  Time-to-event curves for the adverse events (all-cause mortality, myocardial infarction and stroke).
CP: Carotid plaque.
cohort of 1,390 consecutive patients with angiographically-proven CAD and a mean
BMI of 24.7 (3.4) kg/m2 followed up during a mean of 54.2 mo. However, they did not
find a significant relationship with CIMT. Although their inclusion criteria differed
from ours, their findings were similar to other studies and ours in that the CP patients
were older and had a greater prevalence of cardiovascular risk factors. One important
issue is that 33.9% of patients had previous CAD, > 60% had left ventricular ejection
fraction  <  50%,  41.2%  were  treated  with  percutaneous  coronary  angioplasty  or
coronary artery bypass grafting, and they included stent restenosis and target vessel
revascularization  in  the  end  point.  Notably,  these  events  were  not  only  due  to
atherosclerosis progression. Finally, Steinvil et al[34]  found significant associations
between carotid stenosis and all-cause mortality, myocardial infarction, stroke, and
any coronary revascularization procedure in 1,015 patients with significant CAD
(defined as  stenosis  > 70% determined by angiography).  However,  they did not
indicate which treatment was performed (medical,  percutaneous intervention or
surgical)  or  which medication was administered,  and they did not  specify other
important prognostic factors, such as left ventricular ejection fraction.
Although CIMT was associated in classic[12-14]  and contemporary studies[16]  with
overall mortality and cardiovascular events, we were not able to make this association
in this research. CIMT as a surrogate marker of atherosclerosis and predictor of AE is
penalized by the highly variability association in the different studies published so
far[12-14,16,28,35]. Possible explanations for this discrepancy are differences in measurement
methods, definitions of abnormal CIMT, atherosclerosis development between the
vascular beds and in the adaptive response[16,35]. Recent studies have shown CP as a
better  predictor  of  cardiovascular  events  than  CIMT[15].  It  is  possible  that  CP
represents a more advanced atherogenesis stage than CIMT[15,36,37]. This issue explains
why CP groups have a consistently higher prevalence of cardiovascular risk factors
and are older[29,33], and why there was a lower percentage of patients with “healthy
metabolic obesity” in our CP group. Our findings are in consonance with current
European Guidelines  on Cardiovascular  Disease  Prevention in  Clinical  Practice,
where CIMT screening for cardiovascular risk assessment is not recommended (Class
III level A indication), whereas CP assessment is a IIb B recommendation for the same
purpose[1]. In this sense, patients with CP might benefit from aggressive preventive
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Table 3  Univariate analysis of adverse events (all-cause mortality, myocardial infarction and
cerebrovascular accident)
Hazard ratio 95% Confidence interval P value
Age 1.1 1.05-1.15 < 0.001a
Male sex 0.68 0.31-1.50 0.338
Hypertension 2.52 0.75-8.44 0.134
Diabetes mellitus 1.42 0.60-3.38 0.427
Dyslipidaemia 1.89 0.82-4.36 0.134
Current smoker 1.23 0.52-2.95 0.635
Family history of premature CAD 2.17 0.65-7.26 0.21
No cardiovascular risk factors 0.3 0.04-2.24 0.242
High/very high SCORE 2.15 0.98-4.71 0.055
Atrial fibrillation 2.45 0.98-6.10 0.055
CAD PTP ≥ 65% 1.44 0.57-3.60 0.441
BMI, kg/m2 0.93 0.80-1.09 0.381
Fasting plasma glucose 1 0.99-1.01 0.863
Glomerular filtration rate, mL/min/1.73 m2 0.98 0.96-0.99 0.002a
Total cholesterol, mg/dL 1 0.99-1.00 0.333
HDL cholesterol, mg/dL 1 0.95-1.02 0.409
Triglycerides, mg/dL 1 0.99-1.01 0.189
LDL cholesterol, mg/dL 0.99 0.98-1.01 0.294
Left ventricular ejection fraction, % 0.98 0.91-1.06 0.563
Moderate mitral regurgitation 5.29 1.57-17.84 0.007a
Moderate aortic regurgitation 4.24 0.57-31.55 0.158
Moderate tricuspid regurgitation 2.03 0.27-15.19 0.492
METs 0.77 0.66-0.90 0.001a
CIMT 0.91 0.14-6.19 0.926
CIMT > 0.9 mm 0.79 0.33-1.91 0.603
CP presence 2.52 1.17-5.46 0.019a
aP < 0.05. BMI: Body mass index; CAD: Coronary artery disease; CIMT: Carotid intima media thickness; CP:
Carotid  plaque;  HDL cholesterol:  High density  lipoprotein  cholesterol;  LDL cholesterol:  Low density
lipoprotein cholesterol; METs: Metabolic equivalents; PTP: Pre-test probability; SCORE: Systematic Coronary
Risk Evaluation.
measures,  and it  is  important to highlight that in our study not all  patients with
subclinical atherosclerosis were treated after EE, such as very high-risk patients, with
only 59.2% of the CP group receiving statins.
In addition to carotid disease,  functional capacity was associated with AE. As
previously mentioned, functional capacity has been associated with mortality in obese
patients. Barry et al[10]  meta-analysis showed that overweight and obese fit people
presented similar mortality risks to normal weight fit subjects (odds ratio 1.21; 95%
confidence interval (CI) 0.95 to 1.52), whereas obese unfit patients had higher overall
mortality compared to normal weight fit individuals (odds ratio 2.46; 95%CI 1.92 to
3.14). Focusing on obese patients with CAD, Goel et al[38] found a statistical association
between low fitness and mortality in patients with central obesity and a tendency
towards such an association in obese and overweight patients. This was assessed by
measuring the BMI of 855 patients who were enrolled in the Mayo Clinic cardiac
rehabilitation programme,  ultimately revealing that  the association of  BMI with
mortality is complex and altered by fitness level.
It  was  not  surprising  to  find  glomerular  filtration  rate  and  mitral  valve
regurgitation as AE predictors. Several articles have found a significant relationship
between CP and/or CIMT and CAD presence and extension in dialysis or end-stage
renal disease patients[39,40]. Moreover, renal disease has been associated with a worse
prognosis  after  acute  coronary  syndrome[41].  Focusing  in  obese  patients  with
angiographic CAD, chronic kidney disease, defined as glomerular filtration rate < 60
mL/min/1.73 m2, was a strong predictor of cardiac events [hazard ratio (HR) 1.63,
95%CI 1.05-2.53] and overall mortality (HR 2.17, 95%CI 1.54-3.07) in Asiatic subjects
with BMI > 25 kg/m2[42].  On the other hand,  mitral  valve regurgitation has been
identified as an important long-term predictor of adverse outcomes in patients with
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Table 4  Multivariate adverse event analysis (all-cause mortality, myocardial infarction and
cerebrovascular accident)
Hazard ratio 95% Confidence interval P value
Glomerular filtration rate 0.98 0.96-0.99 0.023a
Moderate mitral regurgitation 5.02 1.42-17.75 0.012a
METs 0.83 0.70-0.99 0.034a
CP presence 2.26 1.04-4.95 0.041a
aP < 0.05. CP: Carotid plaque; METs: Metabolic equivalents.
ischaemic heart disease in different clinical scenarios, such as after acute myocardial
infarction[43],  coronary  artery  bypass  graft  surgery[44],  percutaneous  coronary
intervention[45] and even stable CAD[46]. Recently, it has also been associated with a
worse prognosis in patients referred for non-invasive stress testing (dobutamine stress
echocardiography)[47].
The main strength of our study is the restrictive inclusion criteria, including obese
patients with a good prognosis from EE, and the exclusion of potential confounding
factors such as decreased left  ventricular ejection fraction,  previous CAD (and a
subsequent different treatment approach), valvular heart disease that can evolve and
produce AE (like aortic stenosis) and hereditary cardiac disease. Moreover, and in
contrast to the Clinical Outcomes Utilizing Revascularization and Aggressive Drug
Evaluation study where patients were included after coronary angiography[26,27], our
study is in consonance with European guidelines where PTP is first determined and
then non-invasive testing is performed to establish CAD diagnosis and prognosis[17].
The main limitation of our study is that it is a retrospective and single centre study.
For that reason, circulating or urinary biomarkers that might be helpful for guiding
therapy in certain situations (e.g.,  albuminuria in hypertension or DM) were not
analysed. Nevertheless, this strategy is in consonance with 2016 European guidelines
on CVD prevention in clinical practice, which advise against the routine assessment of
circulating or urinary biomarkers as a method to reclassify cardiovascular risk[1].
Another limitation is the number of patients studied. However, even with a small
sample size, this study was big enough to reveal significant differences in several
issues traditionally related to AE in obese and non-obese patients, such as carotid
disease,  cardiorespiratory fitness,  moderate mitral  regurgitation and glomerular
filtration rate. It is possible, however, that other clinical conditions like traditional
cardiovascular risk factors may not be represented in the multivariate analysis due to
insufficient statistical power. Finally, treatments were not included in the AE analysis.
The main reason for this is because baseline medications are difficult to maintain
throughout the study (mean follow-up time 8.2 ± 2.1 years) and can skew the results,
since they can be easily added or removed by different professionals who are in
charge of the patient throughout this extended period of time.
In conclusion, subclinical atherosclerosis defined by CP presence predicts AE in
obese  patients  with  negative  EE.  These  patients  could  benefit  from  aggressive
prevention measures.
ARTICLE HIGHLIGHTS
Research background
Obesity is independently associated with mortality and cardiovascular disease. However, once
cardiovascular disease is established, the studies published so far show contradictory results. On
the other hand, several epidemiological studies have demonstrated an independent association
of carotid disease, defined as carotid plaques or carotid intima media thickness, with overall
mortality and cardiovascular events.
Research motivation
There are no studies addressing the value of subclinical  atherosclerosis,  defined as carotid
disease, and adverse events in obese patients with or without cardiovascular disease.
Research objectives
This study aimed to determine if carotid disease is a predictor of adverse events in obese patients
with coronary artery disease suspicion and negative treadmill stress echocardiography.
Research methods
A retrospective cohort study of patients without significant heart or vascular disease, body mass
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index  ≥  30  kg/m2  and  coronary  artery  disease  suspicion  with  negative  exercise
echocardiography  (EE)  submitted  to  carotid  ultrasonography.  Between  January  2006  and
December  2010,  2000  patients  were  submitted  for  stress  echocardiography  and  carotid
ultrasonography in our centre. Of them, 226 (11.3%) were included. Adverse events were defined
as all-cause mortality, myocardial infarction and cerebrovascular accident.
Research results
We found that 226 patients had body mass indexes ≥ 30 kg/m2, and 76 of them (33.6%) had
carotid plaques. During a mean follow-up time of 8.2 (2.1) years, 27 adverse events were found
(11.9%). Mean event-free survival at 1, 5 and 10 years was 99.1% (0.6), 95.1% (1.4) and 86.5% (2.7),
respectively. In univariate analysis, carotid plaques predicted adverse events (hazard ratio (HR)
2.52, 95% confidence interval (CI) 1.17-5.46; P = 0.019). In multivariable analysis, the presence of
carotid plaques remained a predictor of adverse events (HR 2.26, 95%CI 1.04-4.95, P = 0.041).
Other predictors identified were glomerular filtration rate, metabolic equivalents and moderate
mitral regurgitation.
Research conclusions
This study demonstrates that subclinical atherosclerosis defined by carotid plaques predicts
adverse events in obese patients with negative EE.
Research perspectives
To the best of our knowledge, this is the first article that correlates subclinical atherosclerosis and
adverse events in obese patients, and specifically in obese patients with suspicion of ischaemic
heart disease and a good prognosis from EE. One lesson from this study is that these good
prognosis patients could be further stratified with carotid imaging and, in the case of plaque
presence, benefit from more aggressive prevention measures.
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